Prader-Willi Syndrome Clinical Trial
Official title:
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
This study will investigate sleep behavior in subjects with Angelman Syndrome, Rett Syndrome
or Prader-Willi Syndrome.
The study will also investigate sleep behavior in healthy siblings of subjects with Angelman
Syndrome, Rett Syndrome or Prader-Willi Syndrome. These individuals will serve as control
subjects.
The study will use questionnaires designed to identify sleep disorders and how they affect
behavior and quality of life.
The principal goals of this study are:
1. To see how common sleep disorders are in individuals with Angelman Syndrome, Rett
Syndrome or Prader-Willi Syndrome;
2. To see how sleep disorders affect behavior in these individuals;
3. To see whether sleep disorders and related behavior problems improve or worsen with
age;
4. To see how specific disease conditions relate to sleep disorders and how bad the sleep
disorders are;
5. To develop new treatment options to improve quality of life and behavior issues; and
6. To evaluate current treatment options to improve sleep problems in these individuals.
Subjects with AS, RTT or PWS and normal siblings (controls) will be recruited for study
participation.
Subjects will be recruited from the Rare Disease Clinical Research Network (RDCRN)
consortium registries for AS, RTT and PWS. The RDCRN registries provide listings of
individuals currently enrolled in the RDCRN along with clinical and genetic diagnosis,
medical history and contact information.
The RDCRN consortium sites for AS, RTT and PWS will participate in the study. These sites
will recruit study participants, obtain informed consent and administer the sleep
questionnaires. Institutional Review Board (IRB) approval will be obtained at each RDCRN
consortium site.
"Subjects" is defined as those children with a diagnosis of AS, PWS, and RTT. Subjects will
be divided into separate study arms based upon their medical diagnosis. Study arms will
consist of: 1) AS group, 2) PWS group, 3) RTT group, and 4) control group. "Control group"
is defined as normal healthy siblings of subjects.
Study participants and parents/guardians will be asked to complete the study questionnaires
during the clinic visit. The questionnaires are brief and should not be difficult to
complete. It is anticipated that the questionnaires can be completed in 15-30 minutes. If
parents are unable to complete the questionnaires at the time of their scheduled clinic
visit they will be asked to take the questionnaires home to complete and to mail them back
to the research team. When the research team receives the returned questionnaires they will
be reviewed for completion. If questions are skipped or left blank, a member of the research
team will call the family to complete the missed questions over the phone.
Parents/guardians are allowed to answer the questions on behalf of the study participants
and will be asked to answer all the questions for each age-appropriate questionnaire in
order for the responses to be scored correctly. Subjects with AS, RTT and PWS and normal
siblings will complete the same questionnaire forms.
Study participants will be administered the questionnaires again in 12-24 months at a
follow-up RDCRN clinic visit or by mail to assess the natural history of their sleep
behavior and any sleep disorders.
Study participants identified as having a potential severe sleep disorder based on
questionnaire responses will be contacted or sent a letter by the study investigators and
advised to see a sleep specialist for further evaluation.
Potential "Subjects" must be members of the RDCRN consortium registries with available
contact and clinical diagnostic information on file. These individuals will be invited to
participate in the study at their next regularly scheduled RDCRN visit.
Study recruitment will continue for one year. Subjects with a clinical diagnosis of AS, RTT
or PWS, or normal siblings of these individuals will be recruited for study participation.
The sample size of study participants, including controls, will be based upon the number of
individuals currently enrolled in the RDCRN consortium registries. Currently the combined
number of individuals in the AS, RTT and PWS RDCRN consortium registries is 1082. The
breakdown by disorder is: 678 RTT, 172 AS, 141 PWS. Final sample size will be the total
number of subjects consented during the one year recruitment period. A projected enrollment
total would be approximately 1,000 total individuals ( 500 subjects including 300 RTT, 100
AS, 100 PWS & 500 controls).
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05032326 -
Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
|
Phase 3 | |
Completed |
NCT04526379 -
Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation
|
N/A | |
Terminated |
NCT03458416 -
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
|
Phase 2 | |
Completed |
NCT03718416 -
Natural History Study of Serious Medical Events in PWS
|
||
Completed |
NCT05322096 -
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
|
Phase 2 | |
Completed |
NCT02205450 -
Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
|
||
Terminated |
NCT02179151 -
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
|
Phase 3 | |
Completed |
NCT00375089 -
Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
|
N/A | |
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Recruiting |
NCT05938543 -
Cerebellar TMS and Satiety in Prader-Willi Syndrome
|
N/A | |
Suspended |
NCT05879614 -
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
|
Phase 2 | |
Recruiting |
NCT03031626 -
Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome
|
Phase 4 | |
Withdrawn |
NCT04086810 -
An Open-Label Study of DCCR Tablet in Patients With PWS
|
Phase 3 | |
Completed |
NCT02629991 -
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
|
Phase 2 | |
Recruiting |
NCT02297022 -
Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT02263781 -
PREPL in Health and Disease
|
N/A | |
Completed |
NCT00551343 -
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
|
N/A | |
Recruiting |
NCT06448871 -
Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05939453 -
Impact of Bright Light Therapy on Prader-Willi Syndrome
|
N/A |